{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:49:35Z","timestamp":1790822975366,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016926","name":"Kyoto University Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study aimed to investigate the uptake characteristics of <jats:sup>18<\/jats:sup>F-fluoromisonidazole (FMISO), in mutant-type <jats:italic>isocitrate dehydrogenase<\/jats:italic> (<jats:italic>IDH-mutant,<\/jats:italic> grade 3 and 4) and wild-type <jats:italic>IDH<\/jats:italic> (<jats:italic>IDH-wildtype<\/jats:italic>, grade 4) 2021 WHO classification adult-type diffuse gliomas.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Patients with grade 3 and 4 adult-type diffuse gliomas (n\u2009=\u200935) were included in this prospective study. After registering <jats:sup>18<\/jats:sup>F-FMISO PET and MR images, standardized uptake value (SUV) and apparent diffusion coefficient (ADC) were evaluated in hyperintense areas on fluid-attenuated inversion recovery (FLAIR) imaging (HIA), and in contrast-enhanced tumors (CET) by manually placing 3D volumes of interest. Relative SUV<jats:sub>max<\/jats:sub> (rSUV<jats:sub>max<\/jats:sub>) and SUV<jats:sub>mean<\/jats:sub> (rSUV<jats:sub>mean<\/jats:sub>), 10th percentile of ADC (ADC<jats:sub>10pct<\/jats:sub>), mean ADC (ADC<jats:sub>mean<\/jats:sub>) were measured in HIA and CET, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>rSUV<jats:sub>mean<\/jats:sub> in HIA and rSUV<jats:sub>mean<\/jats:sub> in CET were significantly higher in <jats:italic>IDH-wildtype<\/jats:italic> than in <jats:italic>IDH-mutant<\/jats:italic> (P\u2009=\u20090.0496 and 0.03, respectively). The combination of FMISO rSUV<jats:sub>mean<\/jats:sub> in HIA and ADC<jats:sub>10pct<\/jats:sub> in CET, that of rSUV<jats:sub>max<\/jats:sub> and ADC<jats:sub>10pct<\/jats:sub> in CET, that of rSUV<jats:sub>mean<\/jats:sub> in HIA and ADC<jats:sub>mean<\/jats:sub> in CET, were able to differentiate <jats:italic>IDH-mutant<\/jats:italic> from <jats:italic>IDH-wildtype<\/jats:italic> (AUC 0.80). When confined to astrocytic tumors except for oligodendroglioma, rSUV<jats:sub>max<\/jats:sub>, rSUV<jats:sub>mean<\/jats:sub> in HIA and rSUV<jats:sub>mean<\/jats:sub> in CET were higher for <jats:italic>IDH-wildtype<\/jats:italic> than for <jats:italic>IDH-mutant<\/jats:italic>, but not significantly (P\u2009=\u20090.23, 0.13 and 0.14, respectively). The combination of FMISO rSUV<jats:sub>mean<\/jats:sub> in HIA and ADC<jats:sub>10pct<\/jats:sub> in CET was able to differentiate <jats:italic>IDH-mutant<\/jats:italic> (AUC 0.81).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PET using <jats:sup>18<\/jats:sup>F-FMISO and ADC might provide a valuable tool for differentiating between <jats:italic>IDH<\/jats:italic> mutation status of 2021 WHO classification grade 3 and 4 adult-type diffuse gliomas.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11604-023-01450-x","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T06:02:06Z","timestamp":1684821726000},"page":"1255-1264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of isocitrate dehydrogenase mutation in 2021 world health organization classification grade 3 and 4 glioma adult-type diffuse gliomas with 18F-fluoromisonidazole PET"],"prefix":"10.1007","volume":"41","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1982-3168","authenticated-orcid":false,"given":"Yasutaka","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachi","family":"Okuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Hinoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonoko","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayo","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayoshi","family":"Ishimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Mineharu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"1450_CR1","first-page":"781","volume":"38","author":"S Valable","year":"2011","unstructured":"Valable S, Petit E, Roussel S, Marteau L, Toutain J, Divoux D, et al. Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model. Nucl Med Biol. 2011;38:781\u201393.","journal-title":"Nucl Med Biol"},{"key":"1450_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2967\/jnumed.108.055467","volume":"50","author":"KR Swanson","year":"2009","unstructured":"Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HL, Muzi M, et al. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med. 2009;50:36\u201344.","journal-title":"J Nucl Med"},{"key":"1450_CR3","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00259-017-3677-5","volume":"44","author":"L Bekaert","year":"2017","unstructured":"Bekaert L, Valable S, Lechapt-Zalcman E, Ponte K, Collet S, Constans JM, et al. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. Eur J Nucl Med Mol Imaging. 2017;44:1383\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1450_CR4","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","volume":"122","author":"S Han","year":"2020","unstructured":"Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122:1580\u20139.","journal-title":"Br J Cancer"},{"key":"1450_CR5","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","volume":"19","author":"H Ohgaki","year":"2013","unstructured":"Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19:764\u201372.","journal-title":"Clin Cancer Res"},{"key":"1450_CR6","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807\u201312.","journal-title":"Science"},{"key":"1450_CR7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231\u201351.","journal-title":"Neuro Oncol"},{"key":"1450_CR8","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/nm.2682","volume":"18","author":"C Choi","year":"2012","unstructured":"Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18:624\u20139.","journal-title":"Nat Med"},{"key":"1450_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199379","volume":"13","author":"P Blanc-Durand","year":"2018","unstructured":"Blanc-Durand P, Van Der Gucht A, Verger A, Langen KJ, Dunet V, Bloch J, et al. Voxel-based 18F-FET PET segmentation and automatic clustering of tumor voxels: a significant association with IDH1 mutation status and survival in patients with gliomas. PLoS ONE. 2018;13:e0199379.","journal-title":"PLoS ONE"},{"key":"1450_CR10","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1007\/s00259-018-3969-4","volume":"45","author":"M Unterrainer","year":"2018","unstructured":"Unterrainer M, Winkelmann I, Suchorska B, Giese A, Wenter V, Kreth FW, et al. Biological tumour volumes of gliomas in early and standard 20\u201340 min 18F-FET PET images differ according to IDH mutation status.\u00a0Eur J Nucl Med Mol Imaging. 2018;45:1242\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1450_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00259-017-3846-6","volume":"45","author":"A Verger","year":"2018","unstructured":"Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, et al. Static and dynamic 18 F-FET PET for the characterization of gliomas defined by IDH and 1p\/19q status. Eur J Nucl Med Mol Imaging. 2018;45:443\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1450_CR12","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2967\/jnumed.120.249524","volume":"62","author":"S Collet","year":"2021","unstructured":"Collet S, Guillamo JS, Berro DH, Chakhoyan A, Constans JM, Lechapt-Zalcman E, et al. Simultaneous mapping of vasculature, hypoxia, and proliferation using dynamic susceptibility contrast MRI, (18)F-FMISO PET, and (18)F-FLT PET in relation to contrast enhancement in newly diagnosed glioblastoma. J Nucl Med. 2021;62:1349\u201356.","journal-title":"J Nucl Med"},{"key":"1450_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/0284185117711474","volume":"59","author":"M Kanoto","year":"2018","unstructured":"Kanoto M, Kirii K, Hiraka T, Toyoguchi Y, Sugai Y, Matsuda K, et al. Correlation between hypoxic area in primary brain tumors and WHO grade: differentiation from malignancy using 18F-fluoromisonidazole positron emission tomography. Acta Radiol. 2018;59:229\u201335.","journal-title":"Acta Radiol"},{"key":"1450_CR14","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.neuroimage.2006.01.015","volume":"31","author":"PA Yushkevich","year":"2006","unstructured":"Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006;31:1116\u201328.","journal-title":"Neuroimage"},{"key":"1450_CR15","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1093\/neuonc\/now122","volume":"18","author":"S Burth","year":"2016","unstructured":"Burth S, Kickingereder P, Eidel O, Tichy D, Bonekamp D, Weberling L, et al. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. Neuro Oncol. 2016;18:1673\u20139.","journal-title":"Neuro Oncol"},{"key":"1450_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11060-014-1636-6","volume":"121","author":"Q Wen","year":"2015","unstructured":"Wen Q, Jalilian L, Lupo JM, Molinaro AM, Chang SM, Clarke J, et al. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. J Neurooncol. 2015;121:331\u20139.","journal-title":"J Neurooncol"},{"key":"1450_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13550-021-00752-3","volume":"11","author":"Y Shimizu","year":"2021","unstructured":"Shimizu Y, Nakai Y, Watanabe H, Iikuni S, Ono M, Saji H, et al. Increased [(18)F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors. EJNMMI Res. 2021;11:9.","journal-title":"EJNMMI Res"},{"key":"1450_CR18","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s00259-011-2037-0","volume":"39","author":"K Hirata","year":"2012","unstructured":"Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al. (1)(8)F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging. 2012;39:760\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1450_CR19","first-page":"410","volume":"47","author":"LM Cher","year":"2006","unstructured":"Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410\u20138.","journal-title":"J Nucl Med"},{"key":"1450_CR20","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1158\/0008-5472.CAN-08-3884","volume":"69","author":"MD Szeto","year":"2009","unstructured":"Szeto MD, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord EC, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res. 2009;69:4502\u20139.","journal-title":"Cancer Res"},{"key":"1450_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00259-010-1645-4","volume":"38","author":"N Kawai","year":"2011","unstructured":"Kawai N, Maeda Y, Kudomi N, Miyake K, Okada M, Yamamoto Y, et al. Correlation of biological aggressiveness assessed by 11C-methionine PET and hypoxic burden assessed by 18F-fluoromisonidazole PET in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 2011;38:441\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1450_CR22","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1200\/JCO.2009.21.9832","volume":"27","author":"M Sanson","year":"2009","unstructured":"Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150\u20134.","journal-title":"J Clin Oncol"},{"key":"1450_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00401-015-1454-8","volume":"130","author":"DE Reuss","year":"2015","unstructured":"Reuss DE, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C, et al. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol. 2015;130:407\u201317.","journal-title":"Acta Neuropathol"},{"key":"1450_CR24","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1158\/1078-0432.CCR-10-3194","volume":"17","author":"C Hartmann","year":"2011","unstructured":"Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res. 2011;17:4588\u201399.","journal-title":"Clin Cancer Res"},{"key":"1450_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1148\/radiol.2020191832","volume":"296","author":"J Maynard","year":"2020","unstructured":"Maynard J, Okuchi S, Wastling S, Busaidi AA, Almossawi O, Mbatha W, et al. World health organization grade II\/III glioma molecular status: prediction by MRI morphologic features and apparent diffusion coefficient. Radiology. 2020;296:111\u201321.","journal-title":"Radiology"},{"key":"1450_CR26","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1007\/s00330-018-5351-0","volume":"28","author":"SC Thust","year":"2018","unstructured":"Thust SC, Hassanein S, Bisdas S, Rees JH, Hyare H, Maynard JA, et al. Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II\/III glioma: volumetric segmentation versus two-dimensional region of interest analysis. Eur Radiol. 2018;28:3779\u201388.","journal-title":"Eur Radiol"},{"key":"1450_CR27","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.3174\/ajnr.A5171","volume":"38","author":"Z Xing","year":"2017","unstructured":"Xing Z, Yang X, She D, Lin Y, Zhang Y, Cao D. Noninvasive assessment of IDH mutational status in World Health Organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging. AJNR Am J Neuroradiol. 2017;38:1138\u201344.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1450_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11060-014-1614-z","volume":"121","author":"S Lee","year":"2015","unstructured":"Lee S, Choi SH, Ryoo I, Yoon TJ, Kim TM, Lee SH, et al. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1\/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neurooncol. 2015;121:141\u201350.","journal-title":"J Neurooncol"},{"key":"1450_CR29","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3174\/ajnr.A3803","volume":"35","author":"WL Tan","year":"2014","unstructured":"Tan WL, Huang WY, Yin B, Xiong J, Wu JS, Geng DY. Can diffusion tensor imaging noninvasively detect IDH1 gene mutations in astrogliomas? A retrospective study of 112 cases. AJNR Am J Neuroradiol. 2014;35:920\u20137.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1450_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13550-021-00806-6","volume":"11","author":"K Suzuki","year":"2021","unstructured":"Suzuki K, Kawai N, Ogawa T, Miyake K, Shinomiya A, Yamamoto Y, et al. Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p\/19q codeletion status in newly diagnosed malignant gliomas. EJNMMI Res. 2021;11:67.","journal-title":"EJNMMI Res"},{"key":"1450_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13550-020-00633-1","volume":"10","author":"T Ogawa","year":"2020","unstructured":"Ogawa T, Kawai N, Miyake K, Shinomiya A, Yamamoto Y, Nishiyama Y, et al. Diagnostic value of PET\/CT with (11)C-methionine (MET) and (18)F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification. EJNMMI Res. 2020;10:44.","journal-title":"EJNMMI Res"},{"key":"1450_CR32","first-page":"vdaa172","volume":"3","author":"K Miyake","year":"2021","unstructured":"Miyake K, Suzuki K, Ogawa T, Ogawa D, Hatakeyama T, Shinomiya A, et al. Multiple positron emission tomography tracers for use in the classification of gliomas according to the 2016 World Health Organization criteria. Neurooncol Adv. 2021;3:vdaa172.","journal-title":"Neurooncol Adv."},{"key":"1450_CR33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00259-017-3846-6","volume":"45","author":"A Verger","year":"2018","unstructured":"Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, et al. Static and dynamic (18)F-FET PET for the characterization of gliomas defined by IDH and 1p\/19q status. Eur J Nucl Med Mol Imaging. 2018;45:443\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1450_CR34","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00259-016-3541-z","volume":"44","author":"T Toyonaga","year":"2017","unstructured":"Toyonaga T, Yamaguchi S, Hirata K, Kobayashi K, Manabe O, Watanabe S, et al. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. Eur J Nucl Med Mol Imaging. 2017;44:611\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1450_CR35","first-page":"1851","volume":"45","author":"M Bruehlmeier","year":"2004","unstructured":"Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O\u2013H2O. J Nucl Med. 2004;45:1851\u20139.","journal-title":"J Nucl Med"},{"key":"1450_CR36","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/0360-3016(89)90146-6","volume":"17","author":"JS Rasey","year":"1989","unstructured":"Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys. 1989;17:985\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1450_CR37","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00234-021-02674-2","volume":"63","author":"K Ozturk","year":"2021","unstructured":"Ozturk K, Soylu E, Cayci Z. Correlation between dynamic susceptibility contrast perfusion MRI and genomic alterations in glioblastoma. Neuroradiology. 2021;63:1801\u201310.","journal-title":"Neuroradiology"},{"key":"1450_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3174\/ajnr.A5421","volume":"39","author":"YW Park","year":"2018","unstructured":"Park YW, Han K, Ahn SS, Bae S, Choi YS, Chang JH, et al. Prediction of IDH1-mutation and 1p\/19q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas. AJNR Am J Neuroradiol. 2018;39:37\u201342.","journal-title":"AJNR Am J Neuroradiol"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-023-01450-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-023-01450-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-023-01450-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:15:38Z","timestamp":1698639338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-023-01450-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1450"],"URL":"https:\/\/doi.org\/10.1007\/s11604-023-01450-x","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"23 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Kyoto University Graduate School and Faculty of Medicine, Ethics Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}